Business
Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts
Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical Guidance Click here to access replay of company's April 30, 2025 investor webcast SAN FRANCISCO, CA / ACCESS Newswire / May 7, 2025 /Jaguar ...
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical Guidance","length":123,"tagName":"p"},{"type":"text","content":"Click here to access replay of company's April 30, 2025 investor webcast","length":76,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / May 7, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today provided an overview of expected Q2 - Q4 2025 catalysts related to potential follow-on indications for crofelemer, the company's novel plant-based prescription drug approved by the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER).","length":373,"tagName":"p"},{"type":"text","content":""As discussed during Jaguar's investor webcast last week, 2025 is a year of catalysts for crofelemer in both of our major development programs - our rare disease intestinal failure program and our cancer therapy-related diarrhea program," said Lisa Conte, Jaguar's Founder and CEO. "As a reminder, crofelemer is the only oral drug approved under the FDA's Botanical Guidance. It is not a biologic product. Click here to access the replay of our April 30, 2025 investor webcast."","length":510,"tagName":"p"},{"type":"text","content":"Rare Disease Intestinal Failure ProgramInitial proof-of-concept (POC) results were issued last week for the ongoing investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer in Abu Dhabi in the United Arab Emirates in pediatric patients with intestinal failure due to the rare orphan diseases microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF).","length":386,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The initial POC results, presented April 26, 2025 at the Annual ELITE PED-GI Congress, show crofelemer reduced the required total parenteral nutrition (TPN) and/or supplementary intravenous fluids, collectively referred to as parenteral support, in patients with intestinal failure due to MVID and SBS-IF by up to 27% and 12.5% respectively","length":340,"tagName":"p"}]},{"val":[{"type":"text","content":"Crofelemer also reduced stool volume output, frequency of watery stools, and increased urine output - indicating improved nutrient oral absorption","length":146,"tagName":"p"}]},{"val":[...